Radhika Jadhav

Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India

M. Pawlita, E. Zomawia, M. Tommasino, 2018, Papillomavirus research.

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

M. Pawlita, E. Zomawia, M. Tommasino, 2016, The Lancet. Oncology.

Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study

E. Zomawia, M. Tommasino, D. Anantharaman, 2020, PloS one.

Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study

M. Pawlita, E. Zomawia, M. Tommasino, 2019, Papillomavirus research.

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

E. Zomawia, M. Tommasino, D. Anantharaman, 2021, The Lancet. Oncology.

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination

E. Zomawia, T. Waterboer, P. Sehr, 2022, Vaccine.

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine

E. Zomawia, T. Waterboer, P. Sehr, 2023, Human Vaccines & Immunotherapeutics.